NASCIMBENI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.888
AS - Asia 4.958
EU - Europa 4.544
SA - Sud America 830
Continente sconosciuto - Info sul continente non disponibili 153
AF - Africa 134
OC - Oceania 16
Totale 22.523
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.587
SG - Singapore 1.448
IT - Italia 1.225
CN - Cina 1.201
GB - Regno Unito 1.061
HK - Hong Kong 652
BR - Brasile 608
VN - Vietnam 515
FI - Finlandia 360
DE - Germania 358
SE - Svezia 347
BD - Bangladesh 342
PL - Polonia 264
FR - Francia 210
RU - Federazione Russa 179
CA - Canada 139
IN - India 138
KR - Corea 131
TR - Turchia 114
UA - Ucraina 113
NL - Olanda 76
AR - Argentina 74
ID - Indonesia 73
BG - Bulgaria 72
MX - Messico 56
JP - Giappone 53
IQ - Iraq 45
ZA - Sudafrica 42
ES - Italia 39
EC - Ecuador 36
PK - Pakistan 34
LT - Lituania 31
IE - Irlanda 30
VE - Venezuela 28
AE - Emirati Arabi Uniti 27
BE - Belgio 27
CO - Colombia 27
MY - Malesia 24
EG - Egitto 23
JM - Giamaica 22
RO - Romania 21
UZ - Uzbekistan 21
SA - Arabia Saudita 20
CH - Svizzera 18
GR - Grecia 18
AT - Austria 17
CR - Costa Rica 17
HN - Honduras 17
JO - Giordania 16
PE - Perù 15
AU - Australia 14
CZ - Repubblica Ceca 14
PH - Filippine 13
PY - Paraguay 13
CL - Cile 12
DZ - Algeria 12
KE - Kenya 12
MA - Marocco 11
NP - Nepal 10
TT - Trinidad e Tobago 10
RS - Serbia 9
SI - Slovenia 9
TN - Tunisia 9
TW - Taiwan 9
UY - Uruguay 9
IL - Israele 8
KZ - Kazakistan 8
SV - El Salvador 8
AZ - Azerbaigian 7
BO - Bolivia 7
GT - Guatemala 7
EE - Estonia 6
ET - Etiopia 6
HR - Croazia 6
IR - Iran 6
KG - Kirghizistan 6
MK - Macedonia 6
QA - Qatar 6
PT - Portogallo 5
AL - Albania 4
BB - Barbados 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
LB - Libano 4
OM - Oman 4
BZ - Belize 3
GE - Georgia 3
NI - Nicaragua 3
PR - Porto Rico 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CG - Congo 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GH - Ghana 2
Totale 22.330
Salva come PNG Salva come JPEG
Città #
Ashburn 1.449
Fairfield 1.102
Singapore 928
Santa Clara 903
Hong Kong 630
Southend 620
San Jose 592
Woodbridge 559
Chandler 470
Seattle 459
Houston 457
Wilmington 403
Council Bluffs 384
Cambridge 348
Hefei 331
Helsinki 318
Ann Arbor 317
Nyköping 268
Warsaw 256
New York 237
Dearborn 236
Beijing 233
London 214
Los Angeles 211
Ho Chi Minh City 154
Milan 128
Modena 126
Hanoi 125
Jacksonville 122
Chicago 116
Seoul 108
Boardman 104
Sunnyvale 104
The Dalles 91
San Diego 83
Dallas 73
Rome 72
Lauterbourg 70
São Paulo 69
Sofia 67
Princeton 65
Eugene 62
Buffalo 61
Munich 56
Izmir 54
Shanghai 52
Jakarta 50
Moscow 48
Denver 43
Tokyo 43
Toronto 42
Phoenix 41
Atlanta 37
Salt Lake City 37
Bologna 36
Columbus 35
Orem 35
Frankfurt am Main 32
Da Nang 28
Johannesburg 28
Naples 28
Chennai 27
Manchester 27
Haiphong 26
Nuremberg 26
Poplar 26
Bremen 25
Brooklyn 25
Dublin 25
Montreal 25
Redwood City 24
Palermo 23
Fremont 22
Tampa 22
Biên Hòa 21
Brussels 21
Amsterdam 20
Mexico City 20
Paris 19
Rio de Janeiro 19
San Mateo 19
Tashkent 19
Redondo Beach 18
Stockholm 18
Miano 17
North Bergen 17
Reggio Emilia 17
Schiffdorf 17
Turin 17
Athens 16
Baghdad 16
Dong Ket 16
Mumbai 16
Padova 16
Falls Church 15
Miami 15
Parma 15
Timisoara 15
Washington 15
Bari 14
Totale 15.221
Salva come PNG Salva come JPEG
Nome #
Terapia antialadosteronica e prevenzione della cardiomiopatia cirrotica 771
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 545
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 506
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? 485
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease 433
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis 406
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk 396
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis 394
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 373
MTHFR C677T polymorhism and hyperhomocysteinemia in patients with liver cirrhosis complicated by portal vein thrombosis and hepatocellular carcinoma 361
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV 353
Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes 350
Clinical relevance of liver histopathology and different histological classifications of NASH in adults 342
Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? 338
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 336
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 336
ANTIALDOSTERONE THERAPY IN LIVER CIRRHOSIS: A ROLE FOR PREVENTION OF CIRROTHIC CARDIOMIOPATHY? 334
Drugs and acute porphyrias: reasons for a hazardous relationship 333
Nonalcoholic fatty liver disease: Evolving paradigms 328
A critical appraisal of the use of ultrasound in hepatic steatosis 324
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 322
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? 320
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 320
Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy 318
Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? 314
Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomeres involvement on line pubblication 03-Oct-2012Hepatology- 313
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 308
From NAFLD in clinical practice to answers from guidelines. 304
Insulin resistance in advanced liver cirrhosis : the role of liver dysfunction and the “dissociated” effect on glucose versus lipid and amino acid metabolism 300
Role of Multidrug-Resistance Protein 2 in coproporphyrin transport: results from experimental studies in bile fistula rat models 299
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases 294
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 292
Association between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis 291
Hypothyroidism and nonalcoholic fatty liver disease - A chance association? 288
Alcohol and Steatosis: The Japanese Paradox 285
Global multi-stakeholder endorsement of the MAFLD definition 281
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 274
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 265
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease 264
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? 263
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 262
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy 259
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications 248
Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: The “Musketeer” in the spotlight 246
The genetic basis of Insulin resistance. A brief review 241
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? 241
Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk? 239
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease 234
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 232
Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity? 220
Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases 217
Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? 216
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease 214
Hyperferritinemia and diagnosis of type 1 Gaucher disease 214
Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? 212
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 212
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans 209
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment 208
Sex Differences in NAFLD: State of the Art and Identification of Research Gaps 207
Lipidomic profiling of MASLD: identifying lipid biomarkers for detection and stratification of disease severity 199
Non-alcoholic fatty liver disease: Diagnosis and investigation 199
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry 196
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist 194
Mapping the lipid landscape of MASLD: insights into disease progression through lipidomic patterns 185
Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements 185
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group 182
Frailty after Liver Transplantation: A Complex Unexplored Issue 182
Identifying lipid patterns through lipidomic profiling for MASLD detection and severity stratification 181
Hepatic and extrahepatic malignancies in NAFLD 179
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk 175
Colon cancer in a 12-year-old girl with hypertriglyceridemia 161
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia 161
Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation? 158
Metabolic Disorders in Liver Transplant Recipients: The State of the Art 155
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 153
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study 146
Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease 141
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease 140
Liver transplantation and nonalcoholic steatohepatitis: the state of the art 136
Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease 123
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease 117
Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN) 105
Splenomegaly: Dare to think rare 100
Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study 99
Diagnosi e storia naturale della steatosi epatica non alcolica. Performance e limiti delle tecniche diagnostiche invasive e non invasive e risultati del follow-up a lungo termine delle cirrosi criptogenetiche. 90
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric Group 80
Identifying possible homozygous familial hypercholesterolemia patients: An Italian experts' opinion 79
Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry 32
Totale 22.523
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.954
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.954
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.055 0 0 0 77 83 112 45 53 163 149 247 126
2022/20231.407 133 173 140 123 150 176 27 149 175 17 66 78
2023/2024829 34 53 79 69 162 75 56 82 22 23 56 118
2024/20253.350 82 46 99 191 613 447 319 215 342 201 357 438
2025/20267.938 440 279 583 856 1.108 766 977 373 792 667 523 574
2026/20272.211 264 709 455 783 0 0 0 0 0 0 0 0
Totale 22.523